<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Pulm Med</journal-id><journal-title>BMC Pulmonary Medicine</journal-title><issn pub-type="epub">1471-2466</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2466-5-13</article-id><article-id pub-id-type="pmid">16216128</article-id><article-id pub-id-type="doi">10.1186/1471-2466-5-13</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Hepatocyte and keratinocyte growth factors and their receptors in human lung emphysema</article-title></title-group><contrib-group><contrib id="A1" equal-contrib="yes" corresp="yes" contrib-type="author"><name><surname>Bonay</surname><given-names>Marcel</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>marcel.bonay@bch.aphp.fr</email></contrib><contrib id="A2" equal-contrib="yes" contrib-type="author"><name><surname>Boutten</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><email>anne.boutten@bch.aphp.fr</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Le&#x000e7;on-Malas</surname><given-names>V&#x000e9;ronique</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>anne.boutten@bch.aphp.fr</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Marchal</surname><given-names>Jo&#x000eb;lle</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>marcel.bonay@bch.aphp.fr</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Soler</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>anne.boutten@bch.aphp.fr</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Fournier</surname><given-names>Michel</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>bruno.crestani@bch.aphp.fr</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Leseche</surname><given-names>Guy</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>marcel.bonay@bch.aphp.fr</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Dehoux</surname><given-names>Monique</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><email>monique.dehoux@bch.aphp.fr</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Crestani</surname><given-names>Bruno</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I4">4</xref><email>bruno.crestani@bch.aphp.fr</email></contrib></contrib-group><aff id="I1"><label>1</label>INSERM U 700, Facult&#x000e9; Xavier Bichat, Paris, France</aff><aff id="I2"><label>2</label>Service de Physiologie-Explorations Fonctionnelles, H&#x000f4;pital Bichat-Claude Bernard, Assistance Publique-H&#x000f4;pitaux de Paris, Universit&#x000e9; Paris 7, Paris, France</aff><aff id="I3"><label>3</label>Service de Biochimie A, H&#x000f4;pital Bichat-Claude Bernard, Assistance Publique-H&#x000f4;pitaux de Paris, Universit&#x000e9; Paris 7, Paris, France</aff><aff id="I4"><label>4</label>Service de Pneumologie H&#x000f4;pital Bichat-Claude Bernard, Assistance Publique-H&#x000f4;pitaux de Paris, Universit&#x000e9; Paris 7, Paris, France</aff><aff id="I5"><label>5</label>Service de Pneumologie, H&#x000f4;pital Beaujon, Assistance Publique-H&#x000f4;pitaux de Paris, Universit&#x000e9; Paris 7, Paris, France</aff><aff id="I6"><label>6</label>Service de Chirurgie Thoracique, H&#x000f4;pital Beaujon, Assistance Publique-H&#x000f4;pitaux de Paris, Universit&#x000e9; Paris 7, Paris, France</aff><pub-date pub-type="collection"><year>2005</year></pub-date><pub-date pub-type="epub"><day>10</day><month>10</month><year>2005</year></pub-date><volume>5</volume><fpage>13</fpage><lpage>13</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2466/5/13"/><history><date date-type="received"><day>6</day><month>7</month><year>2005</year></date><date date-type="accepted"><day>10</day><month>10</month><year>2005</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2005 Bonay et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2005</copyright-year><copyright-holder>Bonay et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Bonay Marcel marcel.bonay@bch.aphp.fr </dc:author><dc:title> Hepatocyte and keratinocyte growth factors and their receptors in human lung emphysema </dc:title><dc:date>2005</dc:date><dcterms:bibliographicCitation>BMC Pulmonary Medicine 5(1): 13-. (2005)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2466(2005)5:1&#x0003c;13&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2466</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Hepatocyte and keratinocyte growth factors are key growth factors in the process of alveolar repair. We hypothesized that excessive alveolar destruction observed in lung emphysema involves impaired expression of hepatocyte and keratinocyte growth factors or their respective receptors, c-met and keratinocyte growth factor receptor. The aim of our study was to compare the expression of hepatocyte and keratinocyte growth factors and their receptors in lung samples from 3 groups of patients: emphysema; smokers without emphysema and non-smokers without emphysema.</p></sec><sec sec-type="methods"><title>Methods</title><p>Hepatocyte and keratinocyte growth factor proteins were analysed by immunoassay and western blot; mRNA expression was measured by real time quantitative polymerase chain reaction.</p></sec><sec><title>Results</title><p>Hepatocyte and keratinocyte growth factors, c-met and keratinocyte growth factor receptor mRNA levels were similar in emphysema and non-emphysema patients. Hepatocyte growth factor mRNA correlated negatively with FEV1 and the FEV1/FVC ratio both in emphysema patients and in smokers with or without emphysema. Hepatocyte and keratinocyte growth factor protein concentrations were similar in all patients' groups.</p></sec><sec><title>Conclusion</title><p>The expression of hepatocyte and keratinocyte growth factors and their receptors is preserved in patients with lung emphysema as compared to patients without emphysema. Hepatocyte growth factor mRNA correlates with the severity of airflow obstruction in smokers.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Emphysema is one of the most important cause of respiratory insufficiency with increasing mortality and morbidity [<xref ref-type="bibr" rid="B1">1</xref>]. Lung emphysema is defined pathologically by the destruction of alveolar walls with abnormal permanent enlargement of the air spaces distal to the terminal bronchiole. Precise mechanims contributing to the destruction of alveolar walls remain unclear. Cigarette smoking may induce emphysema by stimulating neutrophils and alveolar macrophages to produce proteases leading to the degradation of the alveolar extracellular matrix and oxidant injury contributing to alveolar destruction [<xref ref-type="bibr" rid="B2">2</xref>]. T lymphocytes contribute to the recruitment and activation of these inflammatory cells and may be involved in the apoptosis and destruction of alveolar epithelium [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. Recent evidence of increased apoptosis of alveolar epithelial and endothelial cells in emphysematous lung suggests that primary alterations of the alveolar epithelium and endothelium might participate in the pathogenesis of the disease [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B8">8</xref>].</p><p>The alveolar epithelium is essential for maintenance of the integrity of the alveolar spaces. Functional restoration of the alveolar epithelium after an injury requires the proliferation and migration of type 2 pneumocytes and their differentiation into type 1 pneumocytes, a tightly regulated phenomenon. Growth factors have been shown to control both phases of the process [<xref ref-type="bibr" rid="B9">9</xref>-<xref ref-type="bibr" rid="B12">12</xref>]. Among these factors, the hepatocyte growth factor (HGF), a heterodimeric protein obtained through the cleavage of an inactive precursor, called 90-kD proHGF, and the keratinocyte growth factor (KGF, also named fibroblast growth factor-7, FGF-7) have been identified as key factors in the process of alveolar repair, both in acute or chronic conditions [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B15">15</xref>]. HGF and KGF respectively act through specific receptors c-met, a membrane bound tyrosine kinase [<xref ref-type="bibr" rid="B16">16</xref>] and FGFR2IIIb, also named KGF-R [<xref ref-type="bibr" rid="B17">17</xref>]. HGF and KGF productions by lung fibroblasts from emphysema have been shown to be reduced when compared with controls [<xref ref-type="bibr" rid="B18">18</xref>]. Recently, Shigemura et al reported that decreased HGF expression due to a failure in sustained endogenous production after injury was associated with emphysema-related histopathologic and physiological changes in a rat model of elastase-induced emphysema [<xref ref-type="bibr" rid="B19">19</xref>]. In this animal model, HGF could have a therapeutic effect [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B19">19</xref>].</p><p>We hypothesized that a defective expression of growth factors involved in human alveolar epithelium repair such as HGF and KGF or their specific receptors might participate in the pathophysiology of lung emphysema. We therefore evaluated the expression of HGF, KGF, and their receptors c-met and KGF-R in lung biopsies from patients with emphysema and from non-emphysema patients, according to their smoking status.</p></sec><sec sec-type="methods"><title>Methods</title><p>This study was approved by the ethics committee of Saint Germain-en-Laye hospital.</p><sec><title>Patients</title><p>Lung samples were obtained during surgery in adult patients (&#x0003e;18 years) from Beaujon university hospital (Clichy, France) and from Bichat university hospital (Paris, France).</p><sec><title>Patients with lung emphysema</title><p>Seventeen patients with radiographically defined emphysema (E group) were included. All patients were active or ex-smokers (Table <xref ref-type="table" rid="T1">1</xref>). CT-scan, pulmonary function tests and &#x003b1;1-AT deficiency were systematically documented. Patients with &#x003b1;1-AT deficiency were excluded. They underwent bullectomy (n = 3), lobectomy (n = 4), lung transplantation (n = 3) or lung volume reduction (n = 7). Pulmonary function tests demonstrated mild to severe airflow obstruction and lung distension (Table <xref ref-type="table" rid="T2">2</xref>). Tissue samples were taken from the resected parenchyma in a macroscopically emphysematous region. Nine patients with emphysema were receiving corticosteroids, either oral (n = 2) and/or inhaled (n = 8). In all patients, lung emphysema was suspected on CT-scan and confirmed by the pathological examination of lung resection samples. The severity of emphysema was approached through pulmonary function abnormalities.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinical characteristics of patients with and without emphysema</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center">Emphysema (E)</td><td align="center">Non-emphysema Smokers (S)</td><td align="center">Non-emphysema Non-Smokers (NS)</td><td align="center">Between groups differences</td></tr></thead><tbody><tr><td align="left">n</td><td align="center">17</td><td align="center">8</td><td align="center">10</td><td></td></tr><tr><td align="left">Age (yr)</td><td align="center">60 &#x000b1; 7.4</td><td align="center">55.8 &#x000b1; 11.2</td><td align="center">52.7 &#x000b1; 19.4</td><td align="center">ns</td></tr><tr><td align="left">Sex ratio F/M</td><td align="center">1/16</td><td align="center">0/8</td><td align="center">2/8</td><td align="center">ns</td></tr><tr><td align="left">Smoking (Pack.yr)</td><td align="center">51 &#x000b1; 21.4*</td><td align="center">33.3 &#x000b1; 14.8</td><td align="center">0</td><td align="center">p &#x0003c; 0.001</td></tr><tr><td align="left">Time since smoking cessation (yearrs)</td><td align="center">7.0 &#x000b1; 7.1</td><td align="center">10 (n = 1)</td><td align="center">Non relevant</td><td align="center">Non relevant</td></tr><tr><td align="left">Active smokers/ex-smokers</td><td align="center">7/10</td><td align="center">7/1</td><td align="center">0/0</td><td align="center">p &#x0003c; 0.001</td></tr></tbody></table><table-wrap-foot><p>*: vs S, p &#x0003c; 0.05; as assessed by Mann-Whitney U-test. ns: non significant.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Pulmonary function tests of patients with and without emphysema.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center">Emphysema (E)</td><td align="center">Non-emphysema Smokers (S)</td><td align="center">Non-emphysema Non-Smokers (NS)</td><td align="center">Between groups differences</td></tr></thead><tbody><tr><td align="left">n</td><td align="center">17</td><td align="center">8</td><td align="center">10</td><td></td></tr><tr><td align="left">FEV<sub>1 </sub>% predicted value (% pred)</td><td align="center">41.7 &#x000b1; 26.6 *,&#x02020;</td><td align="center">71 &#x000b1; 21.3</td><td align="center">82 &#x000b1; 11.1</td><td align="center">p &#x0003c; 0.001</td></tr><tr><td align="left">FEV<sub>1</sub>/FVC</td><td align="center">48.7 &#x000b1; 13.9 *,&#x02020;</td><td align="center">67.6 &#x000b1; 14.8&#x02020;</td><td align="center">86.9 &#x000b1; 11.6</td><td align="center">p &#x0003c; 0.001</td></tr><tr><td align="left">RV (%pred)</td><td align="center">211.6 &#x000b1; 69.4 *,&#x02020;</td><td align="center">123 &#x000b1; 19.7</td><td align="center">88 &#x000b1; 23.9</td><td align="center">p &#x0003c; 0.001</td></tr><tr><td align="left">TLC (%pred)</td><td align="center">121.5 &#x000b1; 17.8 *,&#x02020;</td><td align="center">100 &#x000b1; 10.4 &#x02020;</td><td align="center">83 &#x000b1; 13.5</td><td align="center">p &#x0003c; 0.001</td></tr><tr><td align="left">Pa<sub>O2 </sub>(mmHg)</td><td align="center">69.7 &#x000b1; 10.1 *,&#x02020;</td><td align="center">81 &#x000b1; 15.8</td><td align="center">85.2 &#x000b1; 7.6</td><td align="center">p &#x0003c; 0.005</td></tr><tr><td align="left">Pa<sub>CO2 </sub>(mmHg)</td><td align="center">41.3 &#x000b1; 5</td><td align="center">38.7 &#x000b1; 7.7</td><td align="center">41.8 &#x000b1; 2.6</td><td align="center">ns</td></tr></tbody></table><table-wrap-foot><p>*: vs S, p &#x0003c; 0.01; &#x02020;: vs NS, p &#x0003c; 0.01; as assessed by Mann-Whitney U-test. ns: non significant</p><p>Pa<sub>O2</sub>: arterial oxygen pressure, Pa<sub>CO2</sub>: arterial carbon dioxide pressure, FEV<sub>1</sub>: forced expiratory volume in one second, RV: residual volume, FVC: forced vital capacity, TLC: total lung capacity.</p></table-wrap-foot></table-wrap></sec><sec><title>Non-emphysema patients</title><p>Normal tissue was obtained from 18 non-emphysema patients. Eight patients were smokers (non-emphysema smoker, S) and 10 were non-smokers (non-emphysema non-smoker, NS). S patients were undergoing surgery for the resection of a localised primary lung carcinoma (n = 7) or a benign lesion (n = 1). NS patients were undergoing surgery for the resection of a localised primary lung carcinoma (n = 3), lung metastases (n = 2) or a benign lesion (n = 5). Tissue samples were taken at a site distant from the pathological process and without macroscopical and microscopical evidence of emphysema. S patients had mild to moderate alterations of pulmonary functions tests (table <xref ref-type="table" rid="T2">2</xref>). Increased cumulative tobacco exposure was observed in the E group as compared with the S group (Table <xref ref-type="table" rid="T1">1</xref>). No difference was observed between groups for age and sex ratio (Table <xref ref-type="table" rid="T1">1</xref>). Two patients without emphysema (S group) received inhaled corticosteroids.</p></sec></sec><sec><title>Processing of lung samples</title><p>Lung tissue fragments (about 0.2 cm<sup>3</sup>) were immediately frozen in liquid N<sub>2 </sub>and stored at -80&#x000b0;C until RNA and protein analysis. The histopathology of biopsies was evaluated on paraffin-embedded sections to verify the features of emphysema or normal lungs. The concentration of proteins in biopsies was evaluated from 100 mg of lung samples homogenised with 0.5 ml PBS containing 200 &#x003bc;M phenylmethylsulfonyl fluoride, 1 mg/ml leupeptin and 1 mg/ml aprotinin. The homogenates were centrifuged at 10,000 g for 10 min at 4&#x000b0;C to remove tissue fragments and the supernatants were collected and stored at -80&#x000b0;C until measurement.</p></sec><sec><title>Quantitative analysis of mRNA expression</title><p>Total RNA was extracted from frozen lung tissue and reverse transcribed. Each sample was analysed by reverse transcriptase-real-time polymerase chain reaction (RT-PCR) with specific primers (table <xref ref-type="table" rid="T3">3</xref>) to quantify the expression of mRNA of HGF, KGF, c-met and KGF-R as described previously [<xref ref-type="bibr" rid="B21">21</xref>].</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Primers and PCR cycling conditions.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Primers</td><td align="left">Sequences</td><td align="left">Denaturation</td><td align="left">annealing</td><td align="left">Cycles</td><td align="left">PCR products</td></tr></thead><tbody><tr><td align="left">HGF: Forward<break/>Reverse</td><td align="left">5'-CAGAGGGACAAAGGAAAAGAA-3'<break/>5'-GCAAGTGAATGGAAGTCCTTTA-3'</td><td align="left">94&#x000b0;C, 15s</td><td align="left">58&#x000b0;C, 60s</td><td align="left">40</td><td align="left">167 bp</td></tr><tr><td align="left">KGF: Forward<break/>Reverse</td><td align="left">5'-GAACAAGGAAGGAAAACTCTATGCAA-3'<break/>5'-AAGTGGGCTGTTTTTTGTTCTTTCT-3'</td><td align="left">94&#x000b0;C, 15s</td><td align="left">60&#x000b0;C, 60s</td><td align="left">40</td><td align="left">201 bp</td></tr><tr><td align="left">HGF-R: Forward<break/>Reverse</td><td align="left">5'-GTTTACTTGTTGCAAGGGAGAAGACT-3'<break/>5'-TAGGGTGCCAGCATTTTAGCA-3'</td><td align="left">94&#x000b0;C, 15s</td><td align="left">58&#x000b0;C, 60s</td><td align="left">40</td><td align="left">88 bp</td></tr><tr><td align="left">KGF-R: Forward<break/>Reverse</td><td align="left">5'-TTAAGCAGGAGCATCGCATTG-3'<break/>5'-AACATCCAGGTGGTACGTGTGAT-3'</td><td align="left">94&#x000b0;C, 15s</td><td align="left">60&#x000b0;C, 60s</td><td align="left">40</td><td align="left">151 bp</td></tr><tr><td align="left">Ubiquitin-c: Forward<break/>Reverse</td><td align="left">5'-CACTTGGTCCTGCGCTTGA-3'<break/>5'-TTTTTTGGGAATGCAACAACTTT-3'</td><td align="left">94&#x000b0;C, 15s</td><td align="left">60&#x000b0;C, 60s</td><td align="left">40</td><td align="left">105 bp</td></tr></tbody></table></table-wrap></sec><sec><title>HGF and KGF concentration in lung homogenates</title><p>The proteins HGF and KGF (Quantikine<sup>&#x000ae;</sup>, R&#x00026;D Systems; respective detection limits were 40 and 15 pg/ml for HGF, KGF) were measured in lung homogenates from 26 out of 35 patients when enough lung sample was available (13 E, 5 S, 8 NS).</p></sec><sec><title>HGF western blotting</title><p>Lung homogenates from 4 patients (2 patients with emphysema and 2 patients without emphysema) were examined by Western blotting as previously described [<xref ref-type="bibr" rid="B22">22</xref>].</p></sec><sec><title>Statistical analysis</title><p>Data were analysed by Statview software (Abacus Concepts, Inc.) and displayed as mean &#x000b1; SD. Between-group differences were first assessed by non-parametric analysis of variance (Kruskal-Wallis test). In the case of global significant difference, between two groups comparisons were assessed by the non-parametric Mann-Whitney U-test. Correlations were assessed by the Spearman's rank order test. Categorical data were analysed using the Chi-squared test. A p value &#x0003c; 0.05 was regarded as significant.</p></sec></sec><sec><title>Results</title><sec><title>Lung expression of KGF and KGF receptor</title><p>KGF mRNA (figure <xref ref-type="fig" rid="F1">1A</xref>) and KGF protein (figure <xref ref-type="fig" rid="F1">1C</xref>) were detected in the lungs of all patients. No difference was observed according to the presence of emphysema, and the smoking status.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Expression of KGF (A) and KGF-R (B) mRNA in lung tissue from emphysema and non-emphysema patients</bold>. Results are expressed as a ratio to Ubiquitin in arbitrary units. Individual and mean values (bar) are presented. No difference between groups was found. E: emphysema patients; S and NS: non-emphysematous smoker and non-smoker patients. KGF concentrations in lung homogenates were measured by immunoassay (C). The detection limit was 15 pg/ml. The results are displayed per 1 mg of lung tissue.</p></caption><graphic xlink:href="1471-2466-5-13-1"></graphic></fig><p>KGF-R mRNA (figure <xref ref-type="fig" rid="F1">1B</xref>) was detected in the lungs of all patients. A considerable variability was observed in KGF-R transcript levels in patients with or without emphysema. No difference was observed according to the presence of emphysema and the smoking status.</p><p>KGF mRNA, KGF protein and KGF-R mRNA did not correlate with age, cumulative tobacco exposure, period since smoking cessation, use of inhaled corticosteroids, pulmonary function tests and arterial blood gases.</p></sec><sec><title>Lung expression of HGF and HGF receptor</title><p>Although a considerable variability of HGF mRNA expression was observed, no difference was found between emphysema and non-emphysema groups (figure <xref ref-type="fig" rid="F2">2A</xref>). In emphysema patients, HGF mRNA correlated positively with total lung capacity (TLC) (Rho = 0.51, p = 0.04, n = 17) and negatively with forced expiratory volume in one second (FEV1) (Rho = -0.53, p = 0.03, n = 17) and FEV1/FVC (forced vital capacity) (Rho = -0.54, p = 0.03, n = 17). When all smokers were studied together (smokers with or without emphysema), again, significant correlations between HGF mRNA and FEV1 (Rho = -0.53, p = 0.009, n = 25), and FEV1/FVC (Rho = -0.49, p = 0.017, n = 25) were found. However, the correlation between HGF mRNA and TLC was no more significant (Rho = 0.28, p = 0.18, n = 24) (figure <xref ref-type="fig" rid="F3">3</xref>). There was no correlation between HGF mRNA and cumulative tobacco exposure.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Expression of HGF (A) and c-met (B) mRNA in lung tissue from emphysema and non-emphysema patients</bold>. Results are expressed as a ratio to Ubiquitin in arbitrary units. Individual and mean values (bar) are presented. No difference between groups was found. E: emphysema patients; S and NS: non-emphysematous smoker and non-smoker patients. HGF concentrations in lung homogenates were measured by immunoassay (C). The detection limit was 40 pg/ml. The results are displayed per 1 mg of lung tissue.</p></caption><graphic xlink:href="1471-2466-5-13-2"></graphic></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Correlation between HGF mRNA and pulmonary function in smoker patients</bold>. The ratio of lung HGF to Ubiquitin mRNA was correlated with: (A) forced expiratory volume in one second (FEV1 % predicted), (B) FEV1/FVC (forced vital capacity), but not with (C) total lung capacity (TLC % predicted). Full circle (&#x02022;): emphysema patients; open circle (o): smoker patients without emphysema.</p></caption><graphic xlink:href="1471-2466-5-13-3"></graphic></fig><p>HGF protein was detected in lung homogenates from all patients as assessed by immunoassay. HGF concentration was not different between groups (figure <xref ref-type="fig" rid="F2">2C</xref>). HGF protein correlated positively with residual volume (RV) (Rho = 0.43, p = 0.04, n = 24), TLC (Rho = 0.45, p = 0.03, n = 24) and negatively with FEV1/FVC (Rho = -0.45, p = 0.03, n = 24). Although, no difference of HGF protein concentrations was found between patients' groups, a significant correlation between HGF protein concentrations and cumulative tobacco exposure was observed (Rho = 0.49, p = 0.01, n = 26). As HGF immunoassay measured both proHGF and mature HGF, a western blot analysis was performed to characterize which form of HGF was present in lung homogenates. Western blot (figure <xref ref-type="fig" rid="F4">4</xref>) demonstrated that HGF was present mainly in the cleaved mature form (presence of the 69-kD alpha chain) both in the non-emphysematous and the emphysematous lungs.</p><fig position="float" id="F4"><label>Figure 4</label><caption><p><bold>Western blot analysis of HGF in lung tissue</bold>. Lung homogenates from 4 patients (2 patients with emphysema [E] and 2 non-emphysema patients [NonE]). Recombinant human HGF (R&#x00026;D Systems: according to the manufacturer, rhHGF is a mixture of proHGF and cleaved mature HGF) was loaded and blotted in parallel. HGF was in the cleaved mature form as evidenced by the detection of the 69-kD &#x003b1; chain and the absence of the 90-kD proHGF form.</p></caption><graphic xlink:href="1471-2466-5-13-4"></graphic></fig><p>HGF-R mRNA was detected in all patients. We found no difference between groups (figure <xref ref-type="fig" rid="F2">2B</xref>). Strong correlations were observed between HGF-R mRNA and KGF-R mRNA (Rho = 0.82, p &#x0003c; 0.0001, n = 35) and between HGF mRNA and KGF mRNA (Rho = 0.61, p = 0.004, n = 35) when all patients were taken together.</p></sec></sec><sec><title>Discussion</title><p>The involvement of KGF and HGF in lung repair has been widely documented. Numerous studies in vitro and in vivo have demonstrated that KGF and HGF have protective effects in experimental lung injury [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B23">23</xref>]. To our knowledge, this is the first study of KGF and HGF lung expression in human emphysema. Proteases, oxidant injury [<xref ref-type="bibr" rid="B2">2</xref>], chronic inflammation [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B5">5</xref>] and apoptosis [<xref ref-type="bibr" rid="B6">6</xref>-<xref ref-type="bibr" rid="B8">8</xref>] all contribute to the excessive alveolar wall destruction observed in lung emphysema. We hypothezised that a defect of the lung repair process might be associated with the pathophysiology of lung emphysema. Our results show that lung KGF mRNA and KGF protein are not altered in emphysema. In bleomycin-induced lung injury in rats, KGF and HGF increase in the lung [<xref ref-type="bibr" rid="B24">24</xref>]. A few clinical studies have assessed KGF concentrations in acute lung injury. Verghese et al reported that KGF was not increased in lung edema fluid whereas HGF was increased and associated with higher mortality [<xref ref-type="bibr" rid="B25">25</xref>]. Stern et al reported that KGF and HGF were increased in bronchoalveolar lavage fluid in acute respiratory distress syndrome and associated with a poor prognosis [<xref ref-type="bibr" rid="B13">13</xref>]. Recently, Danan et al observed the highest KGF concentrations in tracheal aspirates from premature infants who survived without bronchopulmonary dysplasia, leading to the conclusion that KGF may prevent injury to lung epithelium and enhanceits repair [<xref ref-type="bibr" rid="B26">26</xref>].</p><p>This study has some methodological limitations. A limited number of patients was studied in each group, especially in non emphysema groups which were mostly composed of lung biopsies obtained at a site distant from localised carcinoma. Furthermore, the patients could only be evaluated at one time point in the course of their disease. Inclusion of smokers without emphysema allowed the differentiation of emphysema-related and tobacco-related events. Because only one tissue sample from surgically resected material was available for examination, the expression of HGF, KGF and their receptors reflects regional disease activity and may be unrepresentative of the entire lung. Indeed, it is well known that emphysema affects different lung regions to a varying extent. Moreover, we evaluated HGF and KGF in lung homogenates only. Future studies should address the expression of HGF and KGF in a more cell-specific fashion.</p><p>In our study, although HGF mRNA lung expression was similar in emphysema and non emphysema patients, a correlation was found between HGF mRNA and the deterioration of pulmonary function tests in emphysema patients. The correlation between airflow obstruction and HGF mRNA level was similarly observed when all smokers with or without emphysema were studied, suggesting that emphysema was not a main determinant of HGF mRNA level in the lung. This strong correlation between airflow obstruction and HGF mRNA in smokers suggests that the increase of HGF mRNA was not related to the presence of emphysema but rather to the degree of airflow obstruction. This observation is supported by the correlation between HGF protein in lung homogenates and the FEV1/FVC ratio in our population. These results are in agreement with the observations of Sauleda et al, who reported that HGF protein concentrations were increased in broncho-alveolar lavage of patients with chronic obstructive pulmonary disease as compared to smokers and non-smoker controls [<xref ref-type="bibr" rid="B27">27</xref>]. Interestingly, the increased lung expression of other growth factors (fibroblast growth factors 1 and 2 and their receptors) has already been reported in chronic obstructive pulmonary disease [<xref ref-type="bibr" rid="B28">28</xref>].</p><p>The mechanisms underlying the correlation between airflow obstruction and HGF mRNA in smokers are unclear. Although speculative, we can propose that the mechanical constraints applied to alveolar tissue secondary to airflow obstruction may stimulate HGF production by alveolar epithelial cells, since Yamamoto et al showed that mechanical stretch induced HGF in alveolar type II cells in vitro [<xref ref-type="bibr" rid="B29">29</xref>]. Furthermore, airway inflammation could contribute to increase local HGF expression by neutrophils [<xref ref-type="bibr" rid="B22">22</xref>] and macrophages [<xref ref-type="bibr" rid="B30">30</xref>]. Interestingly, Aharinejad et al have shown that serum HGF concentrations increased at the time of lung graft rejection, a situation associated with airflow obstruction [<xref ref-type="bibr" rid="B31">31</xref>].</p><p>As HGF and KGF are key factors in the process of alveolar repair [<xref ref-type="bibr" rid="B15">15</xref>], we suggest that their production might be not adapted to the degree of alveolar injury. Indeed, in view of the chronic lung injury observed in emphysema, one could expect an increase of HGF and KGF expression as observed in acute lung injury in rats [<xref ref-type="bibr" rid="B24">24</xref>] and in humans [<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. However the direct assessment of HGF content in lung homogenates is technically difficult. Indeed, HGF is a heparin binding growth factor. High concentrations of inactive precursor of HGF (proHGF) are probably bound to proteoglycans of the extracellular matrix and may not be assayed in the lung homogenates by immunoassay. In this study, western blot analysis showed that HGF was only in the mature active form, both in lung biopsies from emphysema and non-emphysema patients.</p><p>Recently, HGF has been shown to stimulate pulmonary regeneration and to improve pulmonary function in animal models of elastase-induced lung emphysema [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. Preserved expression of HGF-R could allow therapeutic use of growth factors in lung emphysema. Further studies are needed to assess the therapeutic potential of HGF and KGF in lung emphysema.</p></sec><sec><title>Conclusion</title><p>The main results of our study are that: i) KGF and HGF lung expression is preserved in emphysema patients, ii) HGF-R and KGF-R mRNA are consistently expressed in the lung of emphysema patients and are not modified by the smoking status, iii) HGF mRNA correlates with the severity of airflow obstruction in smokers.</p></sec><sec><title>List of abbreviations</title><p>&#x003b1;1-AT: &#x003b1;1-antitrypsin</p><p>E: emphysema</p><p>FEV1: forced expiratory volume in one second</p><p>FGF: fibroblast growth factor</p><p>FVC: forced vital capacity</p><p>HGF: hepatocyte growth factor</p><p>KGF: keratinocyte growth factor</p><p>mRNA: messenger ribonucleic acid</p><p>NS: non-smoker without emphysema</p><p>RT-PCR: reverse transcriptase-real-time polymerase chain reaction</p><p>RV: residual volume</p><p>S: smoker without emphysema</p><p>SD: standard deviation</p><p>TLC: total lung capacity</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>MB and AB equally participated in the design of the study, conducted the majority of the research experiments and drafted the manuscript.</p><p>VL participated in the majority of the research experiments.</p><p>MF participated in the design of the study.</p><p>JM and PS conducted some experiments.</p><p>GL participated in the design of the study.</p><p>MD and BC conceived of the study, participated in its design, and in drafting the manuscript.</p><p>All authors read and approved the final version of the manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2466/5/13/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>Part of this work was supported by the legs Poix, Chancellerie des Universit&#x000e9;s de Paris.</p><p>The authors thank Anne Barnier for helpful technical assistance, and Joanna Shore for helpful criticism of the manuscript.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>PJ</given-names></name></person-group><article-title>Chronic obstructive pulmonary disease</article-title><source>N Engl J Med</source><year>2000</year><volume>343</volume><fpage>269</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">10911010</pub-id><pub-id pub-id-type="doi">10.1056/NEJM200007273430407</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>SD</given-names></name></person-group><article-title>The macrophage in chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>1999</year><volume>160</volume><fpage>S29</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">10556166</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Finkelstein</surname><given-names>R</given-names></name><name><surname>Fraser</surname><given-names>RS</given-names></name><name><surname>Ghezzo</surname><given-names>H</given-names></name><name><surname>Cosio</surname><given-names>MG</given-names></name></person-group><article-title>Alveolar inflammation and its relation to emphysema in smokers</article-title><source>Am J Respir Crit Care Med</source><year>1995</year><volume>152</volume><fpage>1666</fpage><lpage>1672</lpage><pub-id pub-id-type="pmid">7582312</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Retamales</surname><given-names>I</given-names></name><name><surname>Elliott</surname><given-names>WM</given-names></name><name><surname>Meshi</surname><given-names>B</given-names></name><name><surname>Coxson</surname><given-names>HO</given-names></name><name><surname>Pare</surname><given-names>PD</given-names></name><name><surname>Sciurba</surname><given-names>FC</given-names></name><name><surname>Rogers</surname><given-names>RM</given-names></name><name><surname>Hayashi</surname><given-names>S</given-names></name><name><surname>Hogg</surname><given-names>JC</given-names></name></person-group><article-title>Amplification of inflammation in emphysema and its association with latent adenoviral infection</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>164</volume><fpage>469</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">11500352</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turato</surname><given-names>G</given-names></name><name><surname>Zuin</surname><given-names>R</given-names></name><name><surname>Miniati</surname><given-names>M</given-names></name><name><surname>Baraldo</surname><given-names>S</given-names></name><name><surname>Rea</surname><given-names>F</given-names></name><name><surname>Beghe</surname><given-names>B</given-names></name><name><surname>Monti</surname><given-names>S</given-names></name><name><surname>Formichi</surname><given-names>B</given-names></name><name><surname>Boschetto</surname><given-names>P</given-names></name><name><surname>Harari</surname><given-names>S</given-names></name><name><surname>Papi</surname><given-names>A</given-names></name><name><surname>Maestrelli</surname><given-names>P</given-names></name><name><surname>Fabbri</surname><given-names>LM</given-names></name><name><surname>Saetta</surname><given-names>M</given-names></name></person-group><article-title>Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>166</volume><fpage>105</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">12091179</pub-id><pub-id pub-id-type="doi">10.1164/rccm.2111084</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kasahara</surname><given-names>Y</given-names></name><name><surname>Tuder</surname><given-names>RM</given-names></name><name><surname>Cool</surname><given-names>CD</given-names></name><name><surname>Lynch</surname><given-names>DA</given-names></name><name><surname>Flores</surname><given-names>SC</given-names></name><name><surname>Voelkel</surname><given-names>NF</given-names></name></person-group><article-title>Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>163</volume><fpage>737</fpage><lpage>744</lpage><pub-id pub-id-type="pmid">11254533</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kasahara</surname><given-names>Y</given-names></name><name><surname>Tuder</surname><given-names>RM</given-names></name><name><surname>Taraseviciene-Stewart</surname><given-names>L</given-names></name><name><surname>Le Cras</surname><given-names>TD</given-names></name><name><surname>Abman</surname><given-names>S</given-names></name><name><surname>Hirth</surname><given-names>PK</given-names></name><name><surname>Waltenberger</surname><given-names>J</given-names></name><name><surname>Voelkel</surname><given-names>NF</given-names></name></person-group><article-title>Inhibition of VEGF receptors causes lung cell apoptosis and emphysema</article-title><source>J Clin Invest</source><year>2000</year><volume>106</volume><fpage>1311</fpage><lpage>1319</lpage><pub-id pub-id-type="pmid">11104784</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aoshiba</surname><given-names>K</given-names></name><name><surname>Yokohori</surname><given-names>N</given-names></name><name><surname>Nagai</surname><given-names>A</given-names></name></person-group><article-title>Alveolar wall apoptosis causes lung destruction and emphysematous changes</article-title><source>Am J Respir Cell Mol Biol</source><year>2003</year><volume>28</volume><fpage>555</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">12707011</pub-id><pub-id pub-id-type="doi">10.1165/rcmb.2002-0090OC</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Sammak</surname><given-names>PJ</given-names></name><name><surname>Ingbar</surname><given-names>DH</given-names></name></person-group><article-title>Hepatocyte growth factor stimulates migration of type II alveolar epithelial cells on the provisional matrix proteins fibronectin and fibrinogen</article-title><source>Chest</source><year>1999</year><volume>116</volume><fpage>94S</fpage><lpage>95S</lpage><pub-id pub-id-type="pmid">10424614</pub-id><pub-id pub-id-type="doi">10.1378/chest.116.suppl_1.94S</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>RJ</given-names></name><name><surname>Leslie</surname><given-names>CC</given-names></name><name><surname>McCormick-Shannon</surname><given-names>K</given-names></name><name><surname>Deterding</surname><given-names>RR</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Rubin</surname><given-names>JS</given-names></name><name><surname>Shannon</surname><given-names>JM</given-names></name></person-group><article-title>Hepatocyte growth factor is a growth factor for rat alveolar type II cells</article-title><source>Am J Respir Cell Mol Biol</source><year>1994</year><volume>11</volume><fpage>561</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">7524567</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohmichi</surname><given-names>H</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name></person-group><article-title>In vivo mitogenic action of HGF on lung epithelial cells: pulmotrophic role in lung regeneration</article-title><source>Am J Physiol</source><year>1996</year><volume>270</volume><fpage>L1031</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">8764230</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Panos</surname><given-names>RJ</given-names></name><name><surname>Patel</surname><given-names>R</given-names></name><name><surname>Bak</surname><given-names>PM</given-names></name></person-group><article-title>Intratracheal administration of hepatocyte growth factor/scatter factor stimulates rat alveolar type II cell proliferation in vivo</article-title><source>Am J Respir Cell Mol Biol</source><year>1996</year><volume>15</volume><fpage>574</fpage><lpage>581</lpage><pub-id pub-id-type="pmid">8918364</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ware</surname><given-names>LB</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name></person-group><article-title>Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2002</year><volume>282</volume><fpage>L924</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">11943656</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stern</surname><given-names>JB</given-names></name><name><surname>Fierobe</surname><given-names>L</given-names></name><name><surname>Paugam</surname><given-names>C</given-names></name><name><surname>Rolland</surname><given-names>C</given-names></name><name><surname>Dehoux</surname><given-names>M</given-names></name><name><surname>Petiet</surname><given-names>A</given-names></name><name><surname>Dombret</surname><given-names>MC</given-names></name><name><surname>Mantz</surname><given-names>J</given-names></name><name><surname>Aubier</surname><given-names>M</given-names></name><name><surname>Crestani</surname><given-names>B</given-names></name></person-group><article-title>Keratinocyte growth factor and hepatocyte growth factor in bronchoalveolar lavage fluid in acute respiratory distress syndrome patients</article-title><source>Crit Care Med</source><year>2000</year><volume>28</volume><fpage>2326</fpage><lpage>2333</lpage><pub-id pub-id-type="pmid">10921560</pub-id><pub-id pub-id-type="doi">10.1097/00003246-200007000-00024</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crestani</surname><given-names>B</given-names></name><name><surname>Dehoux</surname><given-names>M</given-names></name><name><surname>Hayem</surname><given-names>G</given-names></name><name><surname>Lecon</surname><given-names>V</given-names></name><name><surname>Hochedez</surname><given-names>F</given-names></name><name><surname>Marchal</surname><given-names>J</given-names></name><name><surname>Jaffre</surname><given-names>S</given-names></name><name><surname>Stern</surname><given-names>JB</given-names></name><name><surname>Durand</surname><given-names>G</given-names></name><name><surname>Valeyre</surname><given-names>D</given-names></name><name><surname>Fournier</surname><given-names>M</given-names></name><name><surname>Aubier</surname><given-names>M</given-names></name></person-group><article-title>Differential role of neutrophils and alveolar macrophages in hepatocyte growth factor production in pulmonary fibrosis</article-title><source>Lab Invest</source><year>2002</year><volume>82</volume><fpage>1015</fpage><lpage>1022</lpage><pub-id pub-id-type="pmid">12177240</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weidner</surname><given-names>KM</given-names></name><name><surname>Sachs</surname><given-names>M</given-names></name><name><surname>Birchmeier</surname><given-names>W</given-names></name></person-group><article-title>The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells</article-title><source>J Cell Biol</source><year>1993</year><volume>121</volume><fpage>145</fpage><lpage>154</lpage><pub-id pub-id-type="pmid">8384622</pub-id><pub-id pub-id-type="doi">10.1083/jcb.121.1.145</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dionne</surname><given-names>CA</given-names></name><name><surname>Crumley</surname><given-names>G</given-names></name><name><surname>Bellot</surname><given-names>F</given-names></name><name><surname>Kaplow</surname><given-names>JM</given-names></name><name><surname>Searfoss</surname><given-names>G</given-names></name><name><surname>Ruta</surname><given-names>M</given-names></name><name><surname>Burgess</surname><given-names>WH</given-names></name><name><surname>Jaye</surname><given-names>M</given-names></name><name><surname>Schlessinger</surname><given-names>J</given-names></name></person-group><article-title>Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic fibroblast growth factors</article-title><source>Embo J</source><year>1990</year><volume>9</volume><fpage>2685</fpage><lpage>2692</lpage><pub-id pub-id-type="pmid">1697263</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Plantier</surname><given-names>L</given-names></name><name><surname>Marchand-Adam</surname><given-names>S</given-names></name><name><surname>Marchal-Somme</surname><given-names>J</given-names></name><name><surname>Leseche</surname><given-names>G</given-names></name><name><surname>Fournier</surname><given-names>M</given-names></name><name><surname>Dehoux</surname><given-names>M</given-names></name><name><surname>Aubier</surname><given-names>M</given-names></name><name><surname>Crestani</surname><given-names>B</given-names></name></person-group><article-title>Defect of hepatocyte growth factor production by fibroblasts in human pulmonary emphysema</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2005</year><volume>288</volume><fpage>L641</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">15579628</pub-id><pub-id pub-id-type="doi">10.1152/ajplung.00249.2004</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shigemura</surname><given-names>N</given-names></name><name><surname>Sawa</surname><given-names>Y</given-names></name><name><surname>Mizuno</surname><given-names>S</given-names></name><name><surname>Ono</surname><given-names>M</given-names></name><name><surname>Ohta</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Kaneda</surname><given-names>Y</given-names></name><name><surname>Matsuda</surname><given-names>H</given-names></name></person-group><article-title>Amelioration of pulmonary emphysema by in vivo gene transfection with hepatocyte growth factor in rats</article-title><source>Circulation</source><year>2005</year><volume>111</volume><fpage>1407</fpage><lpage>1414</lpage><pub-id pub-id-type="pmid">15781752</pub-id><pub-id pub-id-type="doi">10.1161/01.CIR.0000158433.89103.85</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishizawa</surname><given-names>K</given-names></name><name><surname>Kubo</surname><given-names>H</given-names></name><name><surname>Yamada</surname><given-names>M</given-names></name><name><surname>Kobayashi</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Mizuno</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name></person-group><article-title>Hepatocyte growth factor induces angiogenesis in injured lungs through mobilizing endothelial progenitor cells</article-title><source>Biochem Biophys Res Commun</source><year>2004</year><volume>324</volume><fpage>276</fpage><lpage>280</lpage><pub-id pub-id-type="pmid">15465014</pub-id><pub-id pub-id-type="doi">10.1016/j.bbrc.2004.09.049</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marchand-Adam</surname><given-names>S</given-names></name><name><surname>Marchal</surname><given-names>J</given-names></name><name><surname>Cohen</surname><given-names>M</given-names></name><name><surname>Soler</surname><given-names>P</given-names></name><name><surname>Gerard</surname><given-names>B</given-names></name><name><surname>Castier</surname><given-names>Y</given-names></name><name><surname>Leseche</surname><given-names>G</given-names></name><name><surname>Valeyre</surname><given-names>D</given-names></name><name><surname>Mal</surname><given-names>H</given-names></name><name><surname>Aubier</surname><given-names>M</given-names></name><name><surname>Dehoux</surname><given-names>M</given-names></name><name><surname>Crestani</surname><given-names>B</given-names></name></person-group><article-title>Defect of hepatocyte growth factor secretion by fibroblasts in idiopathic pulmonary fibrosis</article-title><source>Am J Respir Crit Care Med</source><year>2003</year><volume>168</volume><fpage>1156</fpage><lpage>1161</lpage><pub-id pub-id-type="pmid">12947024</pub-id><pub-id pub-id-type="doi">10.1164/rccm.200212-1514OC</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grenier</surname><given-names>A</given-names></name><name><surname>Chollet-Martin</surname><given-names>S</given-names></name><name><surname>Crestani</surname><given-names>B</given-names></name><name><surname>Delarche</surname><given-names>C</given-names></name><name><surname>El Benna</surname><given-names>J</given-names></name><name><surname>Boutten</surname><given-names>A</given-names></name><name><surname>Andrieu</surname><given-names>V</given-names></name><name><surname>Durand</surname><given-names>G</given-names></name><name><surname>Gougerot-Pocidalo</surname><given-names>MA</given-names></name><name><surname>Aubier</surname><given-names>M</given-names></name><name><surname>Dehoux</surname><given-names>M</given-names></name></person-group><article-title>Presence of a mobilizable intracellular pool of hepatocyte growth factor in human polymorphonuclear neutrophils</article-title><source>Blood</source><year>2002</year><volume>99</volume><fpage>2997</fpage><lpage>3004</lpage><pub-id pub-id-type="pmid">11929792</pub-id><pub-id pub-id-type="doi">10.1182/blood.V99.8.2997</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ray</surname><given-names>P</given-names></name><name><surname>Devaux</surname><given-names>Y</given-names></name><name><surname>Stolz</surname><given-names>DB</given-names></name><name><surname>Yarlagadda</surname><given-names>M</given-names></name><name><surname>Watkins</surname><given-names>SC</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>XF</given-names></name><name><surname>Ray</surname><given-names>A</given-names></name></person-group><article-title>Inducible expression of keratinocyte growth factor (KGF) in mice inhibits lung epithelial cell death induced by hyperoxia</article-title><source>Proc Natl Acad Sci U S A</source><year>2003</year><volume>100</volume><fpage>6098</fpage><lpage>6103</lpage><pub-id pub-id-type="pmid">12732722</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1031851100</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adamson</surname><given-names>IY</given-names></name><name><surname>Bakowska</surname><given-names>J</given-names></name></person-group><article-title>Relationship of keratinocyte growth factor and hepatocyte growth factor levels in rat lung lavage fluid to epithelial cell regeneration after bleomycin</article-title><source>Am J Pathol</source><year>1999</year><volume>155</volume><fpage>949</fpage><lpage>954</lpage><pub-id pub-id-type="pmid">10487852</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Verghese</surname><given-names>GM</given-names></name><name><surname>McCormick-Shannon</surname><given-names>K</given-names></name><name><surname>Mason</surname><given-names>RJ</given-names></name><name><surname>Matthay</surname><given-names>MA</given-names></name></person-group><article-title>Hepatocyte growth factor and keratinocyte growth factor in the pulmonary edema fluid of patients with acute lung injury. Biologic and clinical significance</article-title><source>Am J Respir Crit Care Med</source><year>1998</year><volume>158</volume><fpage>386</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">9700111</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Danan</surname><given-names>C</given-names></name><name><surname>Franco</surname><given-names>ML</given-names></name><name><surname>Jarreau</surname><given-names>PH</given-names></name><name><surname>Dassieu</surname><given-names>G</given-names></name><name><surname>Chailley-Heu</surname><given-names>B</given-names></name><name><surname>Bourbon</surname><given-names>J</given-names></name><name><surname>Delacourt</surname><given-names>C</given-names></name></person-group><article-title>High concentrations of keratinocyte growth factor in airways of premature infants predicted absence of bronchopulmonary dysplasia</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>165</volume><fpage>1384</fpage><lpage>1387</lpage><pub-id pub-id-type="pmid">12016100</pub-id><pub-id pub-id-type="doi">10.1164/rccm.200112-134BC</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sauleda</surname><given-names>J</given-names></name><name><surname>Noguera</surname><given-names>A</given-names></name><name><surname>Blanquer</surname><given-names>D</given-names></name><name><surname>Fuster</surname><given-names>A</given-names></name><name><surname>Pons</surname><given-names>AR</given-names></name><name><surname>Pons</surname><given-names>J</given-names></name><name><surname>Agusti</surname><given-names>A</given-names></name></person-group><article-title>Growth factors in chronic obstructive pulmonary disease [abstract]</article-title><source>Eur Respir J</source><year>2004</year><volume>24 (suppl)</volume><fpage>320s</fpage></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kranenburg</surname><given-names>AR</given-names></name><name><surname>De Boer</surname><given-names>WI</given-names></name><name><surname>Van Krieken</surname><given-names>JH</given-names></name><name><surname>Mooi</surname><given-names>WJ</given-names></name><name><surname>Walters</surname><given-names>JE</given-names></name><name><surname>Saxena</surname><given-names>PR</given-names></name><name><surname>Sterk</surname><given-names>PJ</given-names></name><name><surname>Sharma</surname><given-names>HS</given-names></name></person-group><article-title>Enhanced expression of fibroblast growth factors and receptor FGFR-1 during vascular remodeling in chronic obstructive pulmonary disease</article-title><source>Am J Respir Cell Mol Biol</source><year>2002</year><volume>27</volume><fpage>517</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">12397010</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Teramoto</surname><given-names>H</given-names></name><name><surname>Uetani</surname><given-names>K</given-names></name><name><surname>Igawa</surname><given-names>K</given-names></name><name><surname>Shimizu</surname><given-names>E</given-names></name></person-group><article-title>Stretch induces a growth factor in alveolar cells via protein kinase</article-title><source>Respir Physiol</source><year>2001</year><volume>127</volume><fpage>105</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">11504583</pub-id><pub-id pub-id-type="doi">10.1016/S0034-5687(01)00244-4</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morimoto</surname><given-names>K</given-names></name><name><surname>Amano</surname><given-names>H</given-names></name><name><surname>Sonoda</surname><given-names>F</given-names></name><name><surname>Baba</surname><given-names>M</given-names></name><name><surname>Senba</surname><given-names>M</given-names></name><name><surname>Yoshimine</surname><given-names>H</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Ii</surname><given-names>T</given-names></name><name><surname>Oishi</surname><given-names>K</given-names></name><name><surname>Nagatake</surname><given-names>T</given-names></name></person-group><article-title>Alveolar macrophages that phagocytose apoptotic neutrophils produce hepatocyte growth factor during bacterial pneumonia in mice</article-title><source>Am J Respir Cell Mol Biol</source><year>2001</year><volume>24</volume><fpage>608</fpage><lpage>615</lpage><pub-id pub-id-type="pmid">11350831</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aharinejad</surname><given-names>S</given-names></name><name><surname>Taghavi</surname><given-names>S</given-names></name><name><surname>Klepetko</surname><given-names>W</given-names></name><name><surname>Abraham</surname><given-names>D</given-names></name></person-group><article-title>Prediction of lung-transplant rejection by hepatocyte growth factor</article-title><source>Lancet</source><year>2004</year><volume>363</volume><fpage>1503</fpage><lpage>1508</lpage><pub-id pub-id-type="pmid">15135596</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(04)16148-5</pub-id></citation></ref></ref-list></back></article> 